MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/1878-0261.70029

Медицинская библиотека · Molecular oncology · 2025

MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.

Hu Jie, Ding Ning, Xu Xiaobo, Chen Yedan, Zhang Yong, Liu Jingwen, Zhou Jiebai, Bao Hairong, Zhang Donghui, Song Yijun, Shao Yang, Song Yuanlin

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Although first-line alectinib has prolonged survival in ALK-mutated non-small-cell lung cancers (NSCLCs), the response to treatment varies among patients, and the primary/early development of alectinib resistance mechanisms is still not fully understood. Here, we analyzed molecular profiles of 108 alectinib-treated patients (first-line and second-line after crizotinib) with confirmed relapse by targeted sequencing of cancer-related genes. After first-line treatment, off-target MET and NF2 alterations were more frequent than on-target alterations within the first 6 months, causing primary or early resistance. Conversely, on-target alterations became prevalent after 1 year of first-line alectinib treatment and predominantly after second-line. The incidence of acquired resistance also depended on EML4-ALK variants. In variant 1 (v1), off-target alterations were responsible for 50% of resistance cases after first-line alectinib therapy, whereas on-target mutations had no contribution in this subgroup. In variant 3 (v3), on-target alterations resulted in 46% of resistance cases, whereas only 18% were caused by off-target mutations. After second-line treatment, the most common mutations in v1 were L1196M (42%) and G1269A (25%), while G1202R was detected in 45% of v3 tumors. These findings emphasize the importance of stratifying resistance mechanisms to guide tailored treatment for ALK-positive NSCLCs.

Для цитирования: Hu Jie, Ding Ning, Xu Xiaobo, Chen Yedan, Zhang Yong, Liu Jingwen, Zhou Jiebai, Bao Hairong, Zhang Donghui, Song Yijun, Shao Yang, Song Yuanlin. MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.. Molecular oncology. 2025. DOI: 10.1002/1878-0261.70029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.